Search for stocks /

UTI Asset Management Company Ltd Q2FY26 FY25 – India’s Boomer Fund House Trying to Stay Woke in a Fintech World


1. At a Glance

Welcome to the land of UTI — not your urinary tract infection, but the OG of Indian mutual funds. Founded in 1963 when “mutual funds” sounded like a government savings scheme with a moustache, UTI Asset Management Company Ltd is the granddaddy of the ₹60 lakh crore Indian MF industry. The stock trades around ₹1,402 (as of 17 Oct 2025), giving it a market cap of ₹17,976 crore. It’s almost debt-free (₹0.00 crore), offers a dividend yield of 1.85%, and flexes an ROE of 16.3% with ROCE at 21%.

But Q2FY26 results? Bro, that hurt. Sales at ₹419 crore fell 22.3% QoQ, and PAT at ₹113 crore plunged a dramatic 52.8%. Apparently, even fund managers need mutual funds to manage their own profits. EPS now stands at ₹45.9 annualized, valuing the company at 30.6x earnings — which is fine if you think nostalgia deserves a premium.

Still, they handle a jaw-dropping ₹21.05 lakh crore AUM, a 13.9% YoY growth, commanding 5.04% MF industry share and 27.4% of India’s NPS pie. UTI is basically that old uncle still doing Surya Namaskar while fintech startups are training for Ironman triathlons.


2. Introduction

There’s an unwritten rule in Indian finance — when something starts with “UTI,” it’s either a disease or a legacy brand that refuses to die. Luckily, this one is the latter.

UTI AMC is the OG of the Indian mutual fund universe, predating Sensex, SEBI, and even your dad’s first LIC policy. The company was born when investing meant filling forms in triplicate and waiting for dividends to arrive via post.

Yet, despite all odds, this relic continues to matter. With 1.33 crore live folios, 73,900 distributors, and a ₹21 lakh crore AUM empire, UTI is still in the game. Sure, it no longer leads the pack — that’s now the playground of HDFC AMC and Nippon Life India AMC — but UTI still enjoys trust in small towns where “Nifty 50” sounds like a new tractor model.

Over the past five years, it’s grown quietly — 16.7% sales CAGR and 21.9% PAT CAGR. The growth’s not meteoric, but it’s consistent, like an old Maruti 800 refusing to stall even on a hill climb.

And in 2025, just as everyone started calling AMCs boring, UTI decided to make things spicy — a new CEO (Vetri Subramaniam taking over Feb 2026), expanding global offices, and adding fintech partnerships. Basically, the boomer got a smartphone.


3. Business Model – WTF Do They Even Do?

In one line: They manage your money so you can feel rich while they get actually rich.

UTI AMC collects funds from retail and institutional investors, manages them under various schemes — equity, hybrid, debt, index, ETF, pension, offshore, and PMS — and charges a management fee for the favor.

Their empire is divided like a well-structured thali:

  • UTI Mutual Fund (16.14%) — the masala curry everyone knows.
  • UTI PFL (17.06%) — the pension salad.
  • UTI PMS (65.47%) — the premium dessert.
  • UTI International Ltd (1.21%) — the imported pickle.
  • UTI Alternatives (0.13%) — the boutique chutney.

They run 78 MF schemes (17 equity, 9 hybrid, 23 debt, 3 liquid) across 1.33 crore investors, which is roughly 11% of India’s total MF folios.

The company earns money mostly from management fees, which formed 79.6% of the ₹1,445 crore service revenue in FY25. The rest comes from international management (9.6%), UTI PFL (9.3%), and a sprinkle of rental/interest income — because who doesn’t like passive income?

The structure is simple — gather money, invest smartly, take a slice, and repeat. Think of it as the Uber of finance, but instead of drivers, they have fund managers.


4. Financials Overview

Source table
MetricLatest Qtr (Q2FY26)YoY QtrPrev QtrYoY %QoQ %
Revenue419538547-22.1%-23.4%
EBITDA177348340-49.1%-47.9%
PAT113263254-57.0%-55.5%
EPS (₹)8.818.818.5-53.2%-52.4%

Annualized EPS = ₹35.2 → P/E ≈ 39.8x.

So, UTI’s quarterly profit chart looks like a mountain range — high peaks, deep valleys, and one investor crying somewhere in the middle.


5. Valuation Discussion – Fair Value Range

Let’s estimate using three lenses:

a) P/E Method

Industry P/E ~31.2x.
UTI’s FY25

Continue reading with a premium membership.
Become a member
error: Content is protected !!